Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Healthequity (HQY) EBITDA (2016 - 2026)

Healthequity has reported EBITDA over the past 14 years, most recently at $71.1 million for Q1 2026.

  • Quarterly results put EBITDA at $71.1 million for Q1 2026, up 169.57% from a year ago — trailing twelve months through Jan 2026 was $293.3 million (up 203.29% YoY), and the annual figure for FY2026 was $322.5 million, up 233.45%.
  • EBITDA for Q1 2026 was $71.1 million at Healthequity, down from $78.7 million in the prior quarter.
  • Over the last five years, EBITDA for HQY hit a ceiling of $89.6 million in Q3 2025 and a floor of -$32.8 million in Q1 2022.
  • Median EBITDA over the past 5 years was $14.7 million (2023), compared with a mean of $22.7 million.
  • Biggest five-year swings in EBITDA: plummeted 711.48% in 2022 and later surged 12714.35% in 2024.
  • Healthequity's EBITDA stood at -$1.6 million in 2022, then soared by 994.15% to $14.7 million in 2023, then tumbled by 61.13% to $5.7 million in 2024, then soared by 1279.89% to $78.7 million in 2025, then dropped by 9.69% to $71.1 million in 2026.
  • The last three reported values for EBITDA were $71.1 million (Q1 2026), $78.7 million (Q4 2025), and $89.6 million (Q3 2025) per Business Quant data.